Sapropterin clinical trials
Also written Kuvan, Tetrahydrobiopterin and Phenoptin.
How each study uses sapropterin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sapropterin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 13 Dec 2007 · KUVAN · NDA 022181 (FDA, Drugs@FDA)
- European Union
- 2 Dec 2008 · Kuvan · EMEA/H/C/000943 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
61 studies that test it; most in 2011 (9)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 6 |
| 2011 | 9 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 44
BioMarin Pharmaceutical (15) · Emory University (4) · VA Office of Research and Development (3) · Augusta University (3) · The Children's Health Council (2) · Merck KGaA, Darmstadt, Germany (2) · The University of Texas Health Science Center, Houston (2) · West China Second University Hospital (2)
Often tested with
Tested in the same studies.
Ascorbic Acid (3) · Vitamin E (3) · Thioctic Acid (3) · Antioxidants (1) · Simvastatin (1) · Arginine (1) · Acetovanillone (1) · Allopurinol (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antioxidants source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test sapropterin.
- Apr 2027Neurovascular Transduction During Exercise in Chronic Kidney DiseasePhase 2 · Emory University
- Jul 2027The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent ClaudicationPhase 1 · Louis Messina
Studies
Open first, then newest update. How each study uses sapropterin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 62
- Novel Approaches for Improving Vascular Function in Veterans With HFpEFRecruitingPhase 1VA Office of Research and DevelopmentNCT06312748Written as BH4
- A Single Patient Study of Sapropterin for Multisystem Smooth Muscle Dysfunction SyndromeRecruitingNot applicableGregor AndelfingerNCT07574034Written as Kuvan (Sapropterine)
- Neurovascular Transduction During Exercise in Chronic Kidney DiseaseRecruitingPhase 2Emory UniversityNCT02947750Written as 6R-BH4
- PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDACRecruitingPhase 2Sun Yat-sen UniversityNCT06396637Written as Sapropterin Dihydrochloride
- The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent ClaudicationActive, not recruitingPhase 1Louis MessinaNCT04800692Written as Tetrahydrobiopterin 10 mg/kg
- Evaluation of BH4 Responsiveness in Our PKU PatientsActive, not recruitingPhase 1Sohag UniversityNCT07255599Written as Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
- Exercise and NO in HFrEFCompletedEarly Phase 1VA Office of Research and DevelopmentNCT03136029Written as Tetrahydrobiopterin (BH4)
- Rhode Island Diastolic Dysfunction - Heart FailureCompletedNot applicableProvidence VA Medical CenterNCT02353312Written as Kuvan
- Study on Sapropterin Dihydrochloride Oral Suspension in Healthy SubjectsCompletedPhase 1APR Applied Pharma Research s.a.NCT06481709Written as RLF-OD032
- Study of Kuvan Treatment in Adults With GTPCH DeficiencyCompletedPhase 1/2University of UtahNCT01425528Written as Sapropterin
- Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery DiseaseWithdrawnPhase 4University of NebraskaNCT03493412Written as Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)
- O2 Transport and Utilization in Health and Lung DiseaseWithdrawnPhase 1University of Massachusetts, AmherstNCT04014712Written as Tetrahydrobiopterin
- Kuvan®'s Effect on the Cognition of Children With PhenylketonuriaCompletedPhase 4BioMarin PharmaceuticalNCT01965912Written as Kuvan®
- BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)Status unknownPhase 1West China HospitalNCT05299203Written as Sapropterin dihydrochloride tablets
- A Study for Assessing the Efficacy and Safety of BH4 in Radiation EnteritisStatus unknownPhase 2West China Second University HospitalNCT05138887Written as Tetrahydrobiopterin
- A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin InjuryStatus unknownPhase 1West China Second University HospitalNCT05114226Written as Tetrahydrobiopterin
- Response to Phenylketonuria to Tetrahydrobiopterin (BH4)TerminatedPhase 1The University of Texas Medical Branch, GalvestonNCT00244218Written as tetrahydrobiopterin (BH4)
- A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult SubjectsCompletedPhase 1BioMarin PharmaceuticalNCT00789568Written as sapropterin dihydrochloride
- A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial DysfunctionCompletedPhase 2BioMarin PharmaceuticalNCT00532844Written as Sapropterin Dihydrochloride
- Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and TreatmentCompletedPhase 1/2VA Office of Research and DevelopmentNCT02530996Written as BH4
See all 62 studies that test sapropterin →
Given beside what is tested · 4 — sapropterin is usual care or a partner of the new treatment
- : Vascular Function in Health and DiseaseRecruitingPhase 1D. Walter WrayNCT02966665Written as BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate
- Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed ConditionsCompletedPhase 1APR Applied Pharma Research s.a.NCT06987773Written as Kuvan 100 MG Powder for Oral Solution
- L-arginine Study for Persistent Symptoms of SchizophreniaWithdrawnPhase 2University of Massachusetts, WorcesterNCT04054973Written as Sapropterin Dihydrochloride
- Sex Hormones and Atherosclerosis Prevention in Perimenopausal WomenCompletedEarly Phase 1University of Colorado, DenverNCT02042196Written as KUVAN
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- A Single Patient Study of Sapropterin for Multisystem Smooth Muscle Dysfunction SyndromeNov 5, 2026NCT07574034
Codes
What other systems call sapropterin · ClinicalTrials.gg INT002274
- MeSH (NLM) C003402sapropterinOne source NLM
- UNII (FDA) EGX657432ISAPROPTERINConfirmed FDA, NLM, Wikidata
- RxNorm 753340One source FDA
- Wikidata Q419808sapropterinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78087SapropterinOne source FDA
- DrugBank DB00360One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C003402 | sapropterin | One source NLM |
| UNII (FDA) | EGX657432I | SAPROPTERIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 753340 | — | One source FDA |
| Wikidata | Q419808 | sapropterin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78087 | Sapropterin | One source FDA |
| DrugBank | DB00360 | — | One source Wikidata |
Also registered as 2,4,5-trihydroxybutyrophenone (UNII KN729W3LR0) and sapropterin dihydrochloride (UNII RG277LF5B3 · RxNorm 753341).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.